# Safety Study of LiRIS in Interstitial Cystitis (IC) Patients

> **NCT01150565** · PHASE1 · COMPLETED · sponsor: **Allergan** · enrollment: 18 (actual)

## Conditions studied

- Interstitial Cystitis

## Interventions

- **DRUG:** LiRIS low dose and LiRIS high dose

## Key facts

- **NCT ID:** NCT01150565
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01150565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01150565, "Safety Study of LiRIS in Interstitial Cystitis (IC) Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01150565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*